| ¿µ¹® | activation | ÇÑ±Û | Ȱ¼º, Ȱ¼ºÈ |
|---|---|---|---|
| ¼³¸í | ÀϹÝÀûÀ¸·Î, »ýü³ª »ýü ¹°ÁúÀÌ ±× ±â´ÉÀ» Ȱ¹ßÇÏ°Ô ³ªÅ¸³»°Ô µÇ´Â °Í, ¿¹¸¦ µé¸é ¨ç Ã˸Šµî¿¡¼, ±× Ç¥¸é »óÅÂÀÇ º¯È³ª, ´Ù¸¥ ¹°ÁúÀÇ Ã·°¡ µî¿¡ ÀÇÇÏ¿©, ±× ±â´ÉÀÌ ÇöÀúÇÏ°Ô ³ô¾ÆÁö´Â °Í. ¨è È¿¼ÒÀü±¸Ã¼ÀÇ È°¼ºÈ·Î¼ È¿¼ÒÀÛ¿ëÀ» °¡ÁöÁö ¾Ê´Â È¿¼Ò Àü±¸Ã¼°¡ Ȱ¼ºÀÖ´Â È¿¼Ò·Î º¯È´Â °Í. ¶Ç Ȳȼö¼Ò³ª ½Ã¾Èȼö¼Ò»ê µîÀ¸·Î ÆÄÆÄÀÎÀÌ È°¼ºÈµÇ´Â °æ¿ìµµ ÀÖ´Ù. |
||
| ¿µ¹® | connective tissue | ÇÑ±Û | °áÇÕÁ¶Á÷ |
|---|---|---|---|
| ¼³¸í | ü³»¿¡ ³Î¸® ºÐÆ÷Çϸç, Àå±â, Á¶Á÷»çÀ̸¦ ¸Þ¿ì°í ±×°ÍÀ» ±â°èÀûÀ¸·Î ÁöÁö, Á¶Á÷ÀÌ´Ù. ±×¹Û¿¡ Ç÷°ü, ¸²ÇÁ°ü, ½Å°æÀ» ÀεµÇÏ¸ç ¿µ¾ç, ´ë»ç»ê¹°ÀÇ ¼ö¼Û ¶Ç´Â Àú·ù, ³ª¾Æ°¡¼´Â ¼Õ»ó, °¨¿°¿¡ ´ëÇÑ ¹æ¾î ¶Ç´Â ¼öº¹ µî¿¡µµ ÀÛ¿ëÇÑ´Ù. °áÇÕÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀÌ Ç³ºÎÇϸç, ¼¼Æ÷°£ÁúÀ» ±¸¼ºÇÏ´Â ±âÁú°ú ¼¶À¯ÀÇ ¼º»ó¿¡ µû¶ó °£¿±Á¶Á÷, ¼¶À¯¼º °áÇÕÁ¶Á÷(¼º±ä¼¶À¯¼º °áÇÕÁ¶Á÷, ÃÎÃÎÇÑ ¼¶À¯¼º °áÇÕÁ¶Á÷), Áö¹æÁ¶Á÷, ź¼ºÁ¶Á÷, ¼¼¸Á Á¶Á÷ µîÀ¸·Î ºÐ·ùµÈ´Ù. |
||
| ¿µ¹® | osseous tissue | ÇÑ±Û | »ÀÁ¶Á÷, °ñÁ¶Á÷ |
|---|---|---|---|
| ¼³¸í | °ñ¼¼Æ÷¿Í °ñ¼¼Æ÷ÁÖÀ§ÀÇ µüµüÇÑ Ä®½·Á¶Á÷À¸·Î µÑ·¯½ÎÀÎ ¹ÐÁýµÈ °áÇÕÁ¶Á÷À» ¶æÇÑ´Ù. ÀÌ °ñÁ¶Á÷¿¡ ÀÇÇØ¼ »À°¡ ÀÌ·ç¾îÁ® ÀÎüÀÇ °ñ°ÝÀ» Çü¼ºÇÑ´Ù. |
||
| ¿µ¹® | epithelial tissue | ÇÑ±Û | »óÇÇÁ¶Á÷ |
|---|---|---|---|
| ¼³¸í | »óÇÇ´Â ÇÑ Ãþ ¶Ç´Â ¿©·¯ ÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÆÇ ¸ð¾çÀÇ ±¸Á¶·Î ½ÅüÀÇ Ç¥¸é°ú °ü»ó±¸Á¶ÀÇ ³»°À» µÑ·¯½Î°í ÀÖ´Ù. »óÇǼ¼Æ÷¿Í »óÇǼ¼Æ÷»çÀÌÀÇ ÀûÀº ¾çÀ¸·Î Á¸ÀçÇÏ¿© »óÇÇ»çÀÌÀÇ °ø°£À» ä¿ì°í ÀÖ´Â ¼¼Æ÷°£ÁúÀ» ÇÕÃÄ »óÇÇÁ¶Á÷À̶ó ÇÑ´Ù. »óÇÇÁ¶Á÷¿¡´Â ¿øÄ¢ÀûÀ¸·Î Ç÷°üÀÌ ºÐÆ÷µÇ¾î ÀÖÁö ¾Ê´Ù. |
||
| ¿µ¹® | granulation tissue | ÇÑ±Û | À°¾ÆÁ¶Á÷ |
|---|---|---|---|
| ¼³¸í | ¸ð¼¼Ç÷°üÀÌ Ç³ºÎÇÏ¸ç ¿Õ¼ºÇÏ°Ô Áõ½ÄÀ» °è¼ÓÇÏ´Â ¾î¸° °áÇÕÁ¶Á÷. â»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ, ¿°ÁõÀÌ ¸¸¼ºÀûÀÎ °æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù. |
||
| APSAC | 1) Acylating the Plasminogen Streptokinase Activated Complex 2) Anisoylat... |
|---|---|
| APSAC | acylated plasminogen-streptokinase activator complex; anisoylated plasminogen streptokinase activato... |
| rt-PA | recombinant tissue-Plasminogen Activator = Alteplase |
| tPA | tissue Plasminogen Activator |
| GUSTO | Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries ... |
| PA | Plasminogen activation |
|---|---|
| r-tPA | Recombinant Tissue-Type Plasminogen Activator |
| rt-PA | Recombinant human tissue plasminogen activator |
| rt-PA | Recombinant human tissue-type plasminogen activator |
| r-TPA | Recombinant tissue plasminogen activator |
acute angle
| tissue plasminogen activator | <enzyme> Plasma serine protease, one of a closely related group of plasminogen activators. Contains an EGF like domain and multiple copies of the kringle domain. (18 Nov 1997) |
|---|---|
| plasminogen | <enzyme> The inactive precursor of plasmin. (18 Nov 1997) |
| plasminogen activator | <enzyme> Serine protease that acts on plasminogen to generate plasmin. Has also been implicated in invasiveness and is produced by many normal and invasive cells. The vascular form (tPA, 55 kD) is very similar to tissue plasminogen activator (uPA, 70 kD) and to streptokinase and urokinase. (18 Nov 1997) |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen inactivators | <chemical> Important modulators of the activity of plasminogen activator. Four inhibitors, all belonging to the serpin family of proteins, have been implicated in plasminogen activation inhibition. They are pai-1, pai-2, protease-nexin, and protein c inhibitor (pai-3). All inhibit both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| kidney plasminogen activator | <protein> A precursor to the enzyme urokinase that has blood clotting properties. (14 Nov 1997) |
| activation | <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive. In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation. See: activation product, activation analysis. (09 Oct 1997) |
| activation analysis | <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays. Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many. (09 Oct 1997) |
| activation energy | <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state. (06 May 1997) |
| activation product | <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.) (09 Oct 1997) |
| amino acid activation | The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule. (12 Dec 1998) |
| macrophage activation | The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants. (12 Dec 1998) |
| gene activation | The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development. (05 Mar 2000) |
| Gibbs energy of activation | The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|